Hims & Hers Health (NYSE:HIMS) Shares Down 2% on Insider Selling

Hims & Hers Health, Inc. (NYSE:HIMS - Get Free Report)'s stock price fell 2% during mid-day trading on Thursday following insider selling activity. The company traded as low as $55.60 and last traded at $56.84. 10,953,736 shares were traded during mid-day trading, a decline of 67% from the average session volume of 33,564,293 shares. The stock had previously closed at $58.02.

Specifically, CEO Andrew Dudum sold 125,335 shares of the firm's stock in a transaction that occurred on Monday, July 21st. The shares were sold at an average price of $49.54, for a total transaction of $6,209,095.90. Following the completion of the transaction, the chief executive officer directly owned 92,313 shares of the company's stock, valued at $4,573,186.02. This trade represents a 57.59% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Andrew Dudum sold 47,534 shares of the firm's stock in a transaction that occurred on Wednesday, July 16th. The stock was sold at an average price of $50.25, for a total transaction of $2,388,583.50. Following the transaction, the chief executive officer directly owned 190,126 shares of the company's stock, valued at $9,553,831.50. This represents a 20.00% decrease in their ownership of the stock. The disclosure for this sale can be found here. In related news, CEO Andrew Dudum sold 2,792 shares of the firm's stock in a transaction on Wednesday, July 16th. The shares were sold at an average price of $50.58, for a total value of $141,219.36. Following the completion of the transaction, the chief executive officer owned 92,313 shares of the company's stock, valued at approximately $4,669,191.54. This trade represents a 2.94% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on HIMS. Truist Financial raised their target price on shares of Hims & Hers Health from $45.00 to $48.00 and gave the company a "hold" rating in a research report on Thursday, July 17th. TD Cowen downgraded Hims & Hers Health from a "buy" rating to a "hold" rating and decreased their price target for the company from $44.00 to $30.00 in a research note on Tuesday, April 29th. Bank of America raised their price target on Hims & Hers Health from $22.00 to $26.00 and gave the company an "underperform" rating in a research note on Tuesday, April 29th. Piper Sandler reissued a "neutral" rating and issued a $39.00 target price (up from $35.00) on shares of Hims & Hers Health in a research note on Tuesday, May 6th. Finally, Deutsche Bank Aktiengesellschaft reissued a "hold" rating on shares of Hims & Hers Health in a research note on Wednesday, May 7th. Three research analysts have rated the stock with a sell rating, eight have assigned a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Hold" and an average price target of $39.83.

Hims & Hers Health Stock Performance

The firm's fifty day moving average is $53.15 and its 200 day moving average is $42.77. The firm has a market cap of $12.87 billion, a P/E ratio of 83.33, a P/E/G ratio of 2.11 and a beta of 2.02.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last released its quarterly earnings results on Monday, May 5th. The company reported $0.20 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.12 by $0.08. Hims & Hers Health had a net margin of 9.24% and a return on equity of 22.75%. The firm had revenue of $586.01 million during the quarter, compared to the consensus estimate of $535.21 million. During the same quarter last year, the firm earned $0.05 earnings per share. The company's revenue for the quarter was up 110.7% on a year-over-year basis. As a group, equities research analysts forecast that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

Institutional Investors Weigh In On Hims & Hers Health

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Geneos Wealth Management Inc. bought a new position in shares of Hims & Hers Health in the first quarter valued at approximately $30,000. Summit Securities Group LLC bought a new position in Hims & Hers Health in the 4th quarter valued at $38,000. UMB Bank n.a. grew its stake in Hims & Hers Health by 247.5% in the 1st quarter. UMB Bank n.a. now owns 1,310 shares of the company's stock valued at $39,000 after purchasing an additional 933 shares during the period. BI Asset Management Fondsmaeglerselskab A S bought a new position in Hims & Hers Health during the first quarter valued at about $41,000. Finally, Larson Financial Group LLC grew its position in Hims & Hers Health by 47.7% during the first quarter. Larson Financial Group LLC now owns 1,419 shares of the company's stock valued at $42,000 after buying an additional 458 shares during the period. 63.52% of the stock is owned by institutional investors.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.